Vaccines
13 January 2014
GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients13 January 2014
Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial9 January 2014
PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned9 January 2014
Transgene Announces Topline Preliminary Results from Phase 2b Part of TIME Trial with TG4010 in Non-Small Cell Lung Cancer31 December 2013
Finnish HIV vaccine testing to begin30 December 2013
Heat Biologics Announces Its Phase 1/2 Study of HS-410 in Bladder Cancer Is Open for Enrollment25 December 2013
ImmunoCellular Therapeutics Announces First Patient Receives Vaccine in Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma17 December 2013
Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine17 December 2013
Vical Announces Initiation of Phase 1/2 Trial of a Therapeutic HSV-2 Vaccine for Genital Herpes16 December 2013
CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment16 December 2013
Positive Phase 2 Results from Agenus’ Brain Cancer Vaccine Published in Neuro-Oncology16 December 2013
PharmAthene Receives FDA Notification On SparVax®16 December 2013
BIOMAY AG SUCCESSFULLY COMPLETES INTERIM ANALYSIS OF PHASE IIB STUDY WITH THE INNOVATIVE 3rd GENERATION GRASS POLLEN ALLERGY VACCINE BM3212 December 2013
FDA Advisory committee supports approval of Stallergenes’ Oralair® for the treatment of grass pollen allergy11 December 2013
Lundbeck and Otsuka to Co-Develop a Vaccine, Lu AF20513, Their Third Collaborative Development Project to Tackle Alzheimer’s Disease10 December 2013
Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients6 December 2013
European Commission approves Fluenz Tetra for the prevention of seasonal influenza in children5 December 2013
PaxVax Secures $22 Million Series B Financing5 December 2013
Immunicum Reports Positive Phase I/II-Data for the Therapeutic Cancer Vaccine INTUVAX(R) in the Treatment of Kidney CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports